Praxis Precision Medicines, INC Schedule 13G passive stakes

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have collectively increased their beneficial ownership in Praxis Precision Medicines, Inc. to 5.5%.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed a Schedule 13G, reporting a combined beneficial ownership of 8.9% in Praxis Precision Medicines, Inc.

FMR LLC has reported beneficial ownership of 7.7% of Praxis Precision Medicines Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.09% of Praxis Precision Medicines Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Praxis Precision Medicines Inc. following an internal realignment.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5% beneficial ownership stake in Praxis Precision Medicines, Inc. common stock.

Adage Capital Management, L.P. and its principals reported a 3.83% beneficial ownership stake in Praxis Precision Medicines, Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 5.4% beneficial ownership stake in Praxis Precision Medicines Inc. common stock as of December 31, 2025.

Point72 Asset Management and affiliates, led by Steven A. Cohen, have increased their beneficial ownership in Praxis Precision Medicines, Inc. to 9.6% of the common stock.

Cormorant Asset Management and Bihua Chen report a 4% beneficial ownership stake in Praxis Precision Medicines, Inc. through a Schedule 13G filing.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in Praxis Precision Medicines I as of September 30, 2025.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 12.3% in Praxis Precision Medicines, Inc. common stock as of September 30, 2025.

Morgan Stanley and its subsidiary have reduced their beneficial ownership in Praxis Precision Medicines, Inc. to below the 5% threshold.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.29% beneficial ownership stake in Praxis Precision Medicines, Inc. as of October 31, 2025.

Adage Capital Management, L.P. and its principals have reported an 11.28% beneficial ownership stake in Praxis Precision Medicines, Inc., holding 2,374,085 shares of common stock.

Point72 Asset Management and affiliates, led by Steven A. Cohen, have reported a 7.3% beneficial ownership stake in Praxis Precision Medicines, Inc.

Cormorant Asset Management, LP and Bihua Chen disclose a 7.72% beneficial ownership in Praxis Precision Medicines, Inc. common stock.

Janus Henderson Group plc and its affiliates have reported a beneficial ownership of 12.4% in Praxis Precision Medicines, Inc. common stock.

Adage Capital Management, L.P. and its principals have reported a 9.69% beneficial ownership stake in Praxis Precision Medicines, Inc.

Soleus Capital Master Fund and related entities report a passive 4.6% beneficial ownership in Praxis Precision Medicines, Inc.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 6.69% beneficial ownership stake in Praxis Precision Medicines, Inc.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 11.3% in Praxis Precision Medicines, Inc.'s common stock.

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.9% in Praxis Precision Medicines, Inc. as of March 31, 2025.

Point72 Asset Management and its affiliates, including Steven A. Cohen, have increased their beneficial ownership in Praxis Precision Medicines, Inc. to 5.8% as of May 14, 2025, up from 4.4% as of March 31, 2025.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported beneficial ownership of 4.8% of Praxis Precision Medicines, Inc.'s common stock in an amended Schedule 13G filing.

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 8.57% in Praxis Precision Medicines, Inc. common stock.

Janus Henderson Group PLC has filed a Schedule 13G, revealing a 7.6% beneficial ownership stake in Praxis Precision Medicines, Inc. as of March 31, 2025.

Capital Research Global Investors has filed an amended Schedule 13G, revealing a passive beneficial ownership of 4.2% in Praxis Precision Medicines, Inc. as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 8.64% in Praxis Precision Medicines, Inc.'s common stock as of March 31, 2025.

Soleus Capital Master Fund, L.P. and its affiliated entities have reported a passive 5.0% beneficial ownership stake in Praxis Precision Medicines, Inc., totaling 1,017,740 shares.